Subcutaneous vs Intravenous Immunotherapy in Advanced Melanoma

In this segment, Dr. Morrison introduces the concept of subcutaneous immunotherapy in advanced melanoma and invites Ms. Popolo to explain the key differences between intravenous and subcutaneous administration. The discussion outlines how intravenous therapy typically involves placement of an IV line or port access in an infusion setting, whereas subcutaneous administration delivers medication into the fatty tissue, commonly in the abdomen or thigh. Ms. Popolo provides a practical perspective based on her clinical experience, helping to clarify how these approaches differ in terms of delivery and patient interaction. Dr. Morrison also notes the relatively recent availability of a subcutaneous formulation of nivolumab, marking an evolution in how immunotherapy may be administered. This segment transitions the discussion from traditional treatment methods to newer approaches, setting the stage for deeper exploration of clinical evidence and patient experience in advanced melanoma care.